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Background: Statins are widely used for 
primary and secondary prevention of 
cardiovascular disease (CVD). European 
Society of Cardiology / European 
Atherosclerosis Society (ESC/EAS) guidelines 
recommend LDL-cholesterol targets based on 
CVD risk. 
 
Objectives: This study aimed to determine 
whether LDL-cholesterol targets 
recommended by2016 ESC/EASare achieved 
in routine clinical practice. 
 
Methods: This paper is based on baseline 
data of patients recruited to a controlled 
clinical trial conducted at a tertiary care 
hospital. Participants have been on 
atorvastatin for >2 months. Demographic and 
clinical data were obtained using clinic 
records and interviewer administered 
questionnaires. LDL-cholesterol was assessed 
using Friedewald equation (when triglyceride 
was <400mg/dL) or by direct measurement 
(when triglyceride was ≥400mg/dL). Each 
participant’s CVD risk level and appropriate 
LDL-cholesterol target (very-high CVD 
risk:<70mg/dL; high CVD risk:<100mg/dL; low 
to moderate CVD risk:<115mg/dL) was 
determined according to 2016 ESC/EAS 
Guideline. 
Results: 101 patients were studied. (Women: 
76.2%; mean-age: 61.2:±9.3years). 
Prevalence of coronary heart disease, 
ischaemic stroke, diabetes, hypertension and 
smoking was 30.7%, 4%, 77.2%, 80.2% and 
4%, respectively. According to CVD risk level 
80.2%, 15.8% and 4% were in very-high, high 
and moderate risk categories, respectively. 
Most were on atorvastatin 10mg (45.5%) 
followed by 20mg (43.6%), 40mg (8.9%), 
30mg (1%) and 5mg (1%). Median duration of 
treatment was 41-months. Overall, only 
12.9% had achieved target LDL-cholesterol 
(very-high risk: 7.4%; high risk: 37.5%, 
moderate risk: 25%; p=0.003). Men did better 
than women in achieving target LDL-
cholesterol (men: 29.2%, women: 7.8%; 
p=006). There was no difference based on 
age, comorbidities or atorvastatin dose. 
 
Conclusions: In the study population majority 
has failed to achieve LDL-cholesterol targets 
recommended by 2016 ESC/EAS. Failure to 
achieve targets was more common among 
women and those having very-high CVD risk. 
Reason for suboptimal target achievement 
has to be studied further. 
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